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Purpose
Juvenile dermatomyositis (JDM) is a rare disease which
has been difficult to evaluate objectively due to the low
incidence of disease. The Childhood Arthritis and Rheu-
matology Research Alliance (CARRA) initiated a multi-
center observational registry to create a clinical database
for the major rheumatic diseases of childhood, including
JDM. Initial data from the JDM cohort (prevalent and inci-
dent cases) enrolled in the first 7 months of this ongoing
study are evaluated here.
Methods
Children under 21 yrs with onset of JDM prior to 16 yrs
were included, and subjects or their guardians were con-
sented for the study. IRB approval was obtained at each
enrolling site. JDM was diagnosed by modified Bohan and
Peter criteria. Clinical data were collected from the sub-
jects, guardians, and providers using both general and
JDM-specific case report forms at the time of enrollment.
Data regarding demographics, diagnostic assessment, and
medication exposure were collected. Data were pooled
and stored in a secure centralized database and de-identi-
fied prior to analysis.
Results
Between May 28, 2010 and December 28, 2010, 102 sub-
jects meeting modified criteria for JDM were enrolled
from 23 sites in the U.S. Diagnostic studies commonly
used include electromyography (EMG), muscle biopsy,
and magnetic resonance imaging (MRI). Overall, MRI
was more likely than EMG or muscle biopsy to show
abnormalities. (Table 1) 48 of subjects had 2 or more stu-
dies performed and 54.2% of these subjects reported at
least 1 negative study. In terms of medications, 100% of
subjects have been exposed to corticosteroids during
their course of treatment, and 97% of subjects have been
exposed to methotrexate, suggesting that these medica-
tions are almost universally prescribed for JDM. Medica-
tion history in order of frequency of usage is shown in
Table 2.
Conclusion
MRI was the most common diagnostic modality used and
was the most likely to show abnormalities consistent with
JDM. The false negative rates for MRI, EMG, and muscle
biopsy alone were higher than expected if ascertainment
is correct. Corticosteroids and methotrexate appear to be
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Consistent with JDM 29 (65.9)
EMG (n=86)
Performed 36 (41.9)
Consistent with JDM 25 (69.4)
MRI (n=87)
Performed 74 (85.1)
Consistent with JDM 61 (82.4)
Combination of ≥2 studies (n=91)
Performed 48 (52.7)
2 studies consistent with JDM 26 (54.2)
A study consistent with JDM 22 (45.8)
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standard first line medications used by US pediatric rheu-
matologists for JDM. Pulse corticosteroids, intravenous
gammaglobulin, and hydroxychloroquine have been used
by about half of subjects and further investigation as to
which subgroups receive these medications is warranted.
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All corticosteroids 51 (52.6%) 46 (47.4%) 0 (0.0%) 5
Daily corticosteroids 50 (51.5%) 46 (47.4%) 1 (1.1%) 5
Methotrexate 65 (68.4%) 27 (28.4%) 3 (3.2%) 7
Pulse corticosteroids 4 (4.2%) 48 (50.5%) 43 (45.3%) 7
Hydroxychlorquine 39 (41.1%) 17 (17.9%) 39 (41.1%) 7
Intravenous
gammaglobulin
24 (24.5%) 24 (24.5%) 50 (51.0%) 4
Mycophenolate mofetil 13 (13.7%) 5 (5.3%) 77 (81.1%) 7
Cyclosporine A 4 (4.2%) 5 (5.3%) 86 (90.5%) 7
Rituximab 1 (1.0%) 7 (7.1%) 90 (91.8%) 4
Cyclophosphamide 0 (0.0%) 2 (2.1%) 93 (97.9%) 7
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